NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Omeros Corporation (NASDAQ: OMER)

 
OMER Technical Analysis
5
As on 5th Aug 2022 OMER SHARE Price closed @ 6.83 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 13.43 & Strong Sell for SHORT-TERM with Stoploss of 18.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

OMERSHARE Price

Open 5.70 Change Price %
High 6.89 1 Day 1.10 19.20
Low 5.46 1 Week 2.74 66.99
Close 6.83 1 Month 4.18 157.74
Volume 999200 1 Year -15.84 -69.87
52 Week High 23.53 | 52 Week Low 1.92
 
NASDAQ USA Most Active Stocks
AMD 102.31 -1.54%
MRKR 0.54 63.64%
DKNG 17.96 9.78%
AAPL 165.35 -0.28%
OPEN 5.72 21.70%
BBBY 8.16 32.68%
AMZN 140.80 -1.24%
LYFT 20.28 16.62%
GOVX 3.22 -9.80%
ENDP 0.72 12.50%
 
NASDAQ USA Top Gainers Stocks
REDU 3.41 1075.86%
USWS 5.60 508.70%
NDRAW 0.03 200.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
GPCOR 0.15 114.29%
GSMGW 0.02 100.00%
FTVIW 0.22 83.33%
GBRGR 0.12 71.43%
PTOCW 0.17 70.00%
 
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
CREXW 0.04 -55.56%
MILEW 0.06 -53.85%
HSDT 0.48 -52.94%
BTAQW 0.01 -50.00%
ALACW 0.01 -50.00%
HYZNW 0.37 -49.32%
ACBAW 0.08 -46.67%
ALACR 0.04 -42.86%
IKNX 19.52 -42.42%
 
 
OMER
Daily Charts
OMER
Intraday Charts
Whats New @
Bazaartrend
OMER
Free Analysis
 
OMER Important Levels Intraday
RESISTANCE9.59
RESISTANCE8.70
RESISTANCE8.16
RESISTANCE7.61
SUPPORT6.05
SUPPORT5.50
SUPPORT4.96
SUPPORT4.07
 
OMER Forecast August 2022
4th UP Forecast15.46
3rd UP Forecast12.69
2nd UP Forecast10.98
1st UP Forecast9.27
1st DOWN Forecast4.39
2nd DOWN Forecast2.68
3rd DOWN Forecast0.97
4th DOWN Forecast-1.8
 
OMER Weekly Forecast
4th UP Forecast16.62
3rd UP Forecast13.48
2nd UP Forecast11.54
1st UP Forecast9.60
1st DOWN Forecast4.06
2nd DOWN Forecast2.12
3rd DOWN Forecast0.18
4th DOWN Forecast-2.96
 
OMER Forecast2022
4th UP Forecast47.84
3rd UP Forecast34.69
2nd UP Forecast26.56
1st UP Forecast18.43
1st DOWN Forecast-4.77
2nd DOWN Forecast-12.9
3rd DOWN Forecast-21.03
4th DOWN Forecast-34.18
 
 
OMER Other Details
Segment EQ
Market Capital 399034432.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
OMER Address
OMER
 
OMER Latest News
 
Your Comments and Response on Omeros Corporation
 
OMER Business Profile
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. Address: The Omeros Building, Seattle, WA, United States, 98119
 
2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service